Next wave of successful drug therapy strategies in HER2-positive breast cancer
Next wave of successful drug therapy strategies in HER2-positive breast cancer
Genetic and clinical factors best for predicting late recurrence in oestrogen receptor positive breast cancer
How do we design trials that improve outcome?
Breast cancer heterogeneity no barrier to predictive testing
Measurement variation influences gene expression profiles of breast cancer
Early effect of PI3K-Akt-mTOR blockade on in vitro 18F-FDG uptake in HER2 breast cancer resistant to trastuzumab
The Cancer Genome Atlas (TCGA): comprehensive molecular portraits of breast cancer
Genetic alterations in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
Long-term effectiveness of SERMs for preventing breast cancer
Involvement in the WIN Consortium
The 2013 WIN Symposium
Implementation of individualised treatment and the WINTHER trial